REG
The Board of Directors of Eevia Health Plc has today resolved on a rights issue of approximately SEK 12.1 million, for which the intention was announced on 30 December 2024
THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KON...
REG
COMMUNIQUE FROM THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS IN EEVIA HEALTH PLC
The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on January 17, 2024, in Seinäjoki, Finland, whereby the sh...
REG
MAR
Eevia Health plans to divest its berry-manufacturing-related assets, providing compensation shares as dividends to Eevia's shareholders
Eevia Health Plc ("Eevia" or "The Company") is planning to divest business assets for 2.5 - 3.0 MEUR related to the manufacturing of berry-based ingredients. The aim is to protec...
REG
MAR
Eevia Health Plc plans divesting assets to an eye-health start-up and provide compensation shares as dividends to its shareholder
Eevia Health Plc ("Eevia" or "The Company") is planning to divest business assets related to Retinari™, a prospective eye health compound with auspicious pre-clinical results for...
Eevia Health Plc gears towards a gut health offering with external support
Eevia Health Plc ("Eevia" or "The Company") is planning further to support its turnaround plan with external turnaround experts to improve focus on revenue generation and the str...
Eevia Health Plc receives approval for its top bilberry extract from an old customer and the first new order in 18 months of c. 572 KSEK (50 KEUR)
Eevia Health Plc ("Eevia" or "The Company") has received approval of a second product from an old US nutraceutical customer and received a new 50 KEUR (572 KSEK) sales order. The...
Notice to the Extraordinary General Meeting of Eevia Health Abp
Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 17 January 2025 at 12:00 (Finnish time GMT +3) at the main office...
REG
Eevia Health Plc plans to arrange a rights issue having maximum amount of approximately SEK 12.1 million to finance its strategic reorientation and turnaround plan
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on its intention to execute a rights issue of shares, with preferential rights for the Com...
REG
MAR
Eevia Board Terminates Process for Reverse Takeover
Further to the press release Eevia made on December 2 about Eevia Health Plc ("Eevia" or "The Company") receiving a proposal for a reverse takeover (RTO) from Stemtech Corporatio...
Eevia Health Plc receives a MSEK 1,8 (KUSD 169) sales order
Eevia Health ("Eevia" or "The Company") received a MSEK 1,849 / KUSD 169 blanket sales order for the elderberry extract Feno-Sambucus™ 7 ORGANIC from a distributor in the US.
REG
MAR
Eevia is subject to a possible reverse takeover
Eevia Health Plc ("Eevia" or "The Company") received a proposal for a reverse takeover (RTO) from Stemtech Corporation[1] ("Stemtech"), a US company, on November 10. The proposal...
REG
MAR
Eevia Health Plc: Eevia Health Plc Interim Report Q3 - 2024
The Board and CEO of Eevia Health Plc present the Interim financial report for quarter 3, 2024.
Financial developments and significant events in the third quarter of 2024:
· Net...
Eevia revises financial targets
The new Board of Eevia Health Plc ("Eevia" or "The Company") has approved a new strategic business plan for 2025 - 2026. The new strategy is also a turnaround plan for the Compan...
REG
Eevia revises date for release of Interim report Q3-2024
Eevia Health Plc ("Eevia" or "The Company") will publish its Interim report for the third quarter on November 29 due to the onboarding of a new Board and one large unforeseen urg...
REG
Communique from the EXTRAORDINARY General Meeting OF SHAREHOLDERS in Eevia Health Plc
The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp. Reg. No 2825194-4 (the "Company") was held on November 4, 2024, in Seinäjoki, Finland, whereby the sh...
Eevia goes neck and neck with the market leader in a new whitepaper
Eevia Health Plc ("Eevia" or "The Company") has published a follow-up whitepaper of its research article published on May 2. The whitepaper showcases one of its hero products, Fe...
REG
UPDATE: Dr. Diane Clayton suggested as new Board member in Eevia Health
A press release on October 7 (Correction on November 14) notified the shareholders of Eevia Health Plc ("Eevia" or "The Company") of an Extraordinary General Meeting to be held o...
Eevia Health Plc receives a 587 KSEK (51 KEUR) sales order for a Bilberry extract product
Eevia Health Plc ("Eevia" or "The Company") has received a 51 KEUR sales order from a European nutraceutical brand owner.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.
Webbplats
eeviahealth.com/investors
Handelsinformation
Kurs ()
Förändring ()
